Literature DB >> 10682674

Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy.

P Magnani1, F Fazio, C Grana, C Songini, L Frigerio, S Pecorelli, G Mangili, N Colombo, C D Mariani, G Paganelli.   

Abstract

The diagnosis of recurrent ovarian carcinoma is usually determined at surgical re-exploration since the main non-invasive diagnostic tests have low accuracy. It would be desirable to have a high accuracy non-invasive diagnostic procedure. With this aim, we have assessed the utility of three-step immunoscintigraphy. Thirty patients were intravenously injected with biotinylated monoclonal antibodies MOv18 and B72.3, followed by avidin-streptavidin injection and finally by 111In-biotin. Tumour recurrences were imaged 2 h post radioactivity injection. All patients underwent surgical re-exploration 3-4 days after immunoscintigraphy; the presence of tumour in the area of immunoscintigraphic uptake was evaluated in the biopsied material. Twenty-one patients studied were true-positive, five were true-negative, four were false-positive and none was false-negative. The diagnostic accuracy, positive predictive value and negative predictive value were 87%, 84% and 100% respectively. If these findings are confirmed in a larger number of patients, we expect immunoscintigraphy to be introduced as a cost-effective procedure in the follow-up of patients who have received surgery for ovarian carcinoma, since it promises to reliably identify patients who do not require surgical re-exploration, and guide biopsies when they are indicated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682674      PMCID: PMC2363313          DOI: 10.1054/bjoc.1999.0972

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

Review 1.  Prognostic factors in relation to second-look laparotomy in ovarian cancer.

Authors:  W T Creasman; G L Eddy
Journal:  Baillieres Clin Obstet Gynaecol       Date:  1989-03

2.  A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples.

Authors:  E Seccamani; M Tattanelli; M Mariani; E Spranzi; G A Scassellati; A G Siccardi
Journal:  Int J Rad Appl Instrum B       Date:  1989

3.  Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.

Authors:  P Casalini; E Luison; S Ménard; M I Colnaghi; G Paganelli; S Canevari
Journal:  J Nucl Med       Date:  1997-09       Impact factor: 10.057

4.  Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.

Authors:  D Colcher; J Esteban; J A Carrasquillo; P Sugarbaker; J C Reynolds; G Bryant; S M Larson; J Schlom
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

5.  Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses.

Authors:  S M Larson; J A Carrasquillo; D C Colcher; K Yokoyama; J C Reynolds; S A Bacharach; A Raubitchek; L Pace; R D Finn; M Rotman
Journal:  J Nucl Med       Date:  1991-09       Impact factor: 10.057

6.  Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy.

Authors:  S C Rubin; W J Hoskins; P E Saigo; D Chapman; T B Hakes; M Markman; B Reichman; L Almadrones; J L Lewis
Journal:  Gynecol Oncol       Date:  1991-08       Impact factor: 5.482

7.  Prognosis of surgically determined complete responders in advanced ovarian cancer.

Authors:  D M Gershenson; L J Copeland; J T Wharton; E N Atkinson; N Sneige; C L Edwards; F N Rutledge
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

8.  Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody.

Authors:  F Crippa; G L Buraggi; E Di Re; M Gasparini; E Seregni; S Canevari; M Gadina; M Presti; A Marini; E Seccamani
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components.

Authors:  D Mezzanzanica; S Canevari; S Ménard; S M Pupa; E Tagliabue; A Lanzavecchia; M I Colnaghi
Journal:  Int J Cancer       Date:  1988-04-15       Impact factor: 7.396

10.  Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.

Authors:  S Miotti; S Canevari; S Ménard; D Mezzanzanica; G Porro; S M Pupa; M Regazzoni; E Tagliabue; M I Colnaghi
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

View more
  1 in total

1.  Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.

Authors:  Aurélie Rondon; Sébastien Schmitt; Arnaud Briat; Nancy Ty; Lydia Maigne; Mercedes Quintana; Rosemery Membreno; Brian M Zeglis; Isabelle Navarro-Teulon; Jean-Pierre Pouget; Jean-Michel Chezal; Elisabeth Miot-Noirault; Emmanuel Moreau; Françoise Degoul
Journal:  Theranostics       Date:  2019-09-19       Impact factor: 11.556

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.